Juno Therapeutics, Inc. (JUNO) Shares Bought by Rhumbline Advisers

Leslie Hanson
January 13, 2018

About 120,708 shares traded. It has underperformed by 32.33% the S&P500. Analysts have placed a $55.54 price target on Juno Therapeutics, Inc., suggesting a 10.88% gain from recent close. Iguana Healthcare Management Llc sold 25,000 shares as the company's stock rose 2.20% with the market. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company's stock valued at $160,000 after purchasing an additional 3,559 shares during the last quarter. Juno Therapeutics Inc now has $5.58B valuation. The stock increased 0.95% or $0.47 during the last trading session, reaching $49.4. About 346,042 shares traded. Juno Therapeutics, Inc. (NASDAQ:JUNO) has declined 39.85% since January 12, 2017 and is downtrending. It has underperformed by 56.55% the S&P500.

Investors sentiment increased to 1.44 in 2017 Q3. Its up 0.11, from 1.33 in 2017Q2.

In other Juno Therapeutics news, CFO Steve Harr sold 8,750 shares of the company's stock in a transaction dated Thursday, December 21st. 51 funds opened positions while 53 raised stakes. Cutter Brokerage Incorporated has invested 0.08% in Steel Dynamics, Inc.

Geode Capital Management Llc decreased Daseke Inc stake by 140,158 shares to 175,706 valued at $2.29M in 2017Q3. Peconic Prns Ltd Liability Company holds 570,000 shares or 4.12% of its portfolio. (NASDAQ:JUNO). Baillie Gifford & owns 10.85 million shares. M&T Bancorporation accumulated 13,955 shares. Rhumbline Advisers owned approximately 0.06% of Juno Therapeutics worth $1,795,000 at the end of the most recent quarter. The original version of this report can be viewed at https://stocknewstimes.com/2018/01/10/juno-therapeutics-inc-juno-stake-raised-by-wells-fargo-company-mn.html. Manufacturers Life The holds 0% or 3,293 shares. Rhenman Prtnrs Asset holds 0.57% or 100,000 shares in its portfolio.

Citigroup, a New York-based fund reported 38,930 shares. L & S Advsr stated it has 0.1% of its portfolio in Juno Therapeutics, Inc. (NASDAQ:JUNO). 23,434 were accumulated by Federated Invsts Pa.

Analysts are also projecting an Average Revenue Estimate for Juno Therapeutics Inc.as $19130 in the Current Quarter. (JUNO) delivered a -14.81% earnings surprise. Juno Therapeutics Inc has a 1 year low of $18.90 and a 1 year high of $63.45. After $-1.12 actual earnings per share reported by Juno Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.93 % EPS growth. Juno Therapeutics, Inc. (JUNO) has 0 billion shares outstanding now, 69.93% of which belong to institutional investors.

The consensus recommendation, according to Zacks Investment research, is 1.83. Therefore 50% are positive. Juno Therapeutics Inc had 46 analyst reports since July 22, 2015 according to SRatingsIntel.


Piermont Capital Management Llc increased its stake in Oceaneering International Inc (OII) by 33.05% based on its latest 2017Q3 regulatory filing with the SEC. On Thursday, October 22 the stock rating was reinitiated by Wells Fargo with "Outperform". Goldman Sachs upgraded the stock to "Buy" rating in Thursday, September 17 report. FBR Capital downgraded Juno Therapeutics, Inc.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The firm earned "Mkt Perform" rating on Tuesday, December 6 by Raymond James. Finally, Leerink Swann reissued an "outperform" rating and set a $34.00 target price (down from $45.00) on shares of Juno Therapeutics in a report on Monday, November 28th. The firm has "Equal-Weight" rating by Barclays Capital given on Wednesday, July 6. It also reduced Kt Corp (NYSE:KT) stake by 78,900 shares and now owns 208,700 shares.

Investors sentiment decreased to 0.83 in Q3 2017. Its down 0.43, from 1.26 in 2017Q2. It dived, as 49 investors sold NBL shares while 150 reduced holdings. 43 funds opened positions while 159 raised stakes. 190.76 million shares or 1.92% less from 194.51 million shares in 2017Q2 were reported. Los Angeles Cap Management Equity has 111,261 shares. (NYSE:HBI) for 44,395 shares. Endurance Wealth invested 0.03% of its portfolio in Hanesbrands Inc. (NASDAQ:JUNO) for 2.28M shares. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Meiji Yasuda Asset Mngmt invested in 0.05% or 17,552 shares. Employees Retirement Association Of Colorado stated it has 0% of its portfolio in Juno Therapeutics, Inc. 579,674 were accumulated by Parametric Port Assoc Ltd Co. (NASDAQ:JUNO). Moreover, Capital has 0.02% invested in Juno Therapeutics, Inc. Washington-based Tradewinds Capital Management Lc has invested 0% in Juno Therapeutics, Inc. Hl Financial Service Ltd Llc holds 0.02% of its portfolio in Hanesbrands Inc. (NYSE:HBI). Atria Invs Llc holds 0.02% in Hanesbrands Inc.

Among 30 analysts covering Noble Energy Inc.

Among 2 analysts covering 51job (NASDAQ:JOBS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 73% are positive. Noble Energy Inc. had 98 analyst reports since July 21, 2015 according to SRatingsIntel. TheStreet upgraded Steel Dynamics, Inc. Cowen & Co maintained the stock with "Buy" rating in Thursday, October 26 report. The firm has "Buy" rating given on Tuesday, May 23 by Bank of America. The company was maintained on Friday, October 6 by Morgan Stanley. The stock of Noble Energy, Inc. On Wednesday, November 23 the stock rating was maintained by Maxim Group with "Buy". The firm earned "Buy" rating on Monday, August 24 by Standpoint Research.

Since August 4, 2017, it had 0 insider purchases, and 2 insider sales for $732,156 activity.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER